| Clinical impact of using [</SUP> 18<//SUP> F] AlF-NOTA-octreotide PET/CT instead of [</SUP> 68<//SUP> Ga] Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter … H Leupe, E Pauwels, T Vandamme, B van den Broeck, W Lybaert, ... Journal Of Neuroendocrinology, 2024 | | 2024 |
| Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial H Leupe, E Pauwels, T Vandamme, B Van den Broeck, W Lybaert, ... Journal of Neuroendocrinology, e13420, 2024 | | 2024 |
| The Metabolic and Lipidomic Fingerprint of Torin1 Exposure in Mouse Embryonic Fibroblasts Using Untargeted Metabolomics R Robeyns, A Sisto, E Iturrospe, KM da Silva, M van de Lavoir, ... Metabolites 14 (5), 248, 2024 | | 2024 |
| Druglike, 18F-labeled PET Tracers Targeting Fibroblast Activation Protein M Tanc, N Filippi, Y Van Rymenant, S Grintsevich, I Pintelon, ... Journal of Medicinal Chemistry 67 (9), 7068-7087, 2024 | | 2024 |
| Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) M Mileva, EGE de Vries, T Guiot, Z Wimana, AL Deleu, CP Schröder, ... NPJ breast cancer 10 (1), 4, 2024 | 4 | 2024 |
| Druglike, ¹⁸F-labeled PET tracers targeting fibroblast activation protein (FAP) M Tanc, N Filippi, Y Van Rymenant, S Grintsevich, I Pintelon, ... Journal of medicinal chemistry.-Washington, DC, 1963, currens, 2024 | | 2024 |
| Synthesis and evaluation of a fluorinated PET imaging probe targeting fibroblast activation protein (FAP) N Filippi, Y Van Rymenant, L Cianni, S Stroobants, I De Meester, ... Nuclear Medicine and Biology 126, 108595, 2023 | | 2023 |
| Characterization of Structurally Diverse 18F-Labeled d-TCO Derivatives as a PET Probe for Bioorthogonal Pretargeted Imaging K Adhikari, J Dewulf, C Vangestel, P Van der Veken, S Stroobants, ... ACS omega 8 (41), 38252-38262, 2023 | 2 | 2023 |
| Impact on clinical management when using [18F] AlFNOTA-octreotide instead of [68Ga] Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results H Leupe, E Pauwels, T Vandamme, B Van den Broeck, W Lybaert, ... European Journal Of Nuclear Medicine And Molecular Imaging 50 (SUPPL 1 …, 2023 | | 2023 |
| First-in-human study of a novel cell death tracer [99mTc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers T Metelerkamp Cappenberg, S De Schepper, C Vangestel, ... EJNMMI Radiopharmacy and Chemistry 8 (1), 20, 2023 | | 2023 |
| MRI apparent diffusion coefficient (ADC) as a biomarker of tumour response: imaging-pathology correlation in patients with hepatic metastases from colorectal cancer (EORTC 1423) A Jackson, R Pathak, NM deSouza, Y Liu, BKM Jacobs, S Litiere, ... Cancers 15 (14), 3580, 2023 | 3 | 2023 |
| Prospective comparison of [</SUP> 18<//SUP> F] AlF-NOTA-octreotide PET/MRI to [</SUP> 68<//SUP> Ga] Ga-DOTATATE PET/CT in neuroendocrine tumor patients L Boeckxstaens, E Pauwels, V Vandecaveye, W Deckers, F Cleeren, ... Ejnmmi Research 13 (1), 2023 | | 2023 |
| Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients L Boeckxstaens, E Pauwels, V Vandecaveye, W Deckers, F Cleeren, ... EJNMMI research 13 (1), 53, 2023 | 7 | 2023 |
| 18F-AlF-NOTA-octreotide outperforms 68Ga-DOTATATE/NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study E Pauwels, F Cleeren, T Tshibangu, M Koole, K Serdons, L Boeckxstaens, ... Journal of Nuclear Medicine 64 (4), 632-638, 2023 | 38 | 2023 |
| 18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies Y Dockx, C Vangestel, S De Bruycker, T Van den Wyngaert, M Huizing, ... Cancer Biotherapy & Radiopharmaceuticals 38 (1), 51-61, 2023 | 2 | 2023 |
| Validation, kinetic modeling, and test-retest reproducibility of [18F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice D Bertoglio, F Zajicek, SD Lombaerde, A Miranda, S Stroobants, Y Wang, ... Journal of Cerebral Blood Flow & Metabolism 42 (10), 1867-1878, 2022 | 8 | 2022 |
| Safety, biodistribution and internal radiation dosimetry of the cell death tracer [Tc99m]-Duramycin in healthy volunteers T Cappenberg, S De Schepper, F Elvas, C Vangestel, S De Lombaerde, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 49 (SUPPL 1 …, 2022 | | 2022 |
| [</SUP> 18<//SUP> F] AlF-NOTA-octreotide vs.[</SUP> 68<//SUP> Ga] Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective … E Pauwels, F Cleeren, T Tshibangu, M Koole, K Serdons, L Boeckxstaens, ... European Journal Of Nuclear Medicine And Molecular Imaging 49 (SUPPL 1 …, 2022 | | 2022 |
| Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy F Soffers, N Helsen, T Van den Wyngaert, L Carp, OS Hoekstra, ... EJNMMI research 12 (1), 34, 2022 | 2 | 2022 |
| Characterization of the novel mutant-huntingtin-aggregate-directed PET radioligand [11C] CHDI-009R in a mouse model of Huntington's disease F Zajicek, J Verhaeghe, S De Lombaerde, A Miranda, S Stroobants, ... JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 42 (1_ SUPPL), 9-10, 2022 | | 2022 |
